Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-400,154
Closed -$5.88M 3261
2025
Q3
$5.88M Sell
400,154
-238,673
-37% -$2.43M ﹤0.01% 1830
2025
Q2
$6.27M Sell
638,827
-397,130
-38% -$3.29M ﹤0.01% 1768
2025
Q1
$7.53M Buy
1,035,957
+749,465
+262% +$6.55M ﹤0.01% 1712
2024
Q4
$2.24M Sell
286,492
-3,420
-1% -$28.2K ﹤0.01% 2341
2024
Q3
$2.15M Buy
289,912
+6,811
+2% +$57.3K ﹤0.01% 2381
2024
Q2
$2.27M Sell
283,101
-267,493
-49% -$2.39M ﹤0.01% 2323
2024
Q1
$6.41M Buy
550,594
+308,205
+127% +$3.41M ﹤0.01% 1849
2023
Q4
$2.71M Sell
242,389
-155,413
-39% -$1.43M ﹤0.01% 2276
2023
Q3
$6.14M Buy
397,802
+21,795
+6% +$366K ﹤0.01% 1760
2023
Q2
$7.13M Buy
+376,007
New +$6.6M ﹤0.01% 1715
2022
Q2
Sell
-38,906
Closed -$149K 3326
2022
Q1
$149K Sell
38,906
-17,234
-31% -$111K ﹤0.01% 3223
2021
Q4
$664K Sell
56,140
-4,152
-7% -$65.6K ﹤0.01% 2994
2021
Q3
$1.28M Buy
60,292
+5,678
+10% +$104K ﹤0.01% 2884
2021
Q2
$1.02M Sell
54,614
-10,298
-16% -$230K ﹤0.01% 2996
2021
Q1
$1.54M Sell
64,912
-7,476
-10% -$173K ﹤0.01% 2729
2020
Q4
$1.76M Buy
72,388
+5,712
+9% +$146K ﹤0.01% 2570
2020
Q3
$1.71M Buy
+66,676
New +$2.11M ﹤0.01% 2458
2020
Q2
Sell
-43,630
Closed -$1.1M 3301
2020
Q1
$1.1M Buy
+43,630
New +$1.28M ﹤0.01% 2480

Other funds holding ETNB

Nuveen's ETNB Position: Q4 2025 in Review

Nuveen sold out of 89bio (ETNB) in Q4 2025, closing a stake of 400,154 shares — an estimated $5.88M sold.

Nuveen first reported a position in ETNB in Q1 2020 and held it in 18 quarters. The position peaked at $7.53M in Q1 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Nuveen reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Nuveen sold 400,154 89bio shares in Q4 2025, an estimated $5.88M.
  • Nuveen first reported a position in 89bio in Q1 2020 and held it in 18 quarters.
  • Nuveen's 89bio position peaked at $7.53M in Q1 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Nuveen's 13F filing for Q4 2025, filed 12 Feb 2026.